Daxor

DXR

Börsenwert 58,7 Mio. $

FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care. Key Highlights: Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026) OAK RIDGE, Tenn.

New Clinical Studies Validate BVA™ Technology in High-Acuity Heart Failure Populations to Enhance Care OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting. Strong clinician engagement at the conference underscored the need for Daxor's next-generation blood volume analysis (BVA™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%.

Making its ASN debut, Daxor's BVA™ technology delivers precise volume measurement to optimize fluid management and improve complex kidney care. Key Highlights: Commercial Presence: Daxor exhibiting at Booth #390 during ASN Kidney Week 2026 in Denver, CO (October 21–25, 2026).

FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA™) designed for rapid clinical adoption across hospital systems and outpatient clinics Clinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patients On-Site Demonstrations: Daxor participating in HFSA's dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October 9–12, 2026) OAK RIDGE, Tenn.

Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026.

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor's presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA™).

New Technology Expands Daxor's Diagnostic Capabilities to Enable Continuous, Remote Tracking of Blood Volume Status Using Wearable Sensors, Enhancing Care for Heart Failure, Syncope, Anemia, and Polycythemia OAK RIDGE, TN, June 02, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor.

Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA™) technology at the MedAxiom CV Transforum Spring'26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.